The data-driven longevity industry is facing a hard reality check. Despite public fascination with epigenetic clocks like GrimAge and PhenoAge, experts argue these tools currently offer more research promise than personal utility.
Peter Attia, on his podcast The Peter Attia Drive, detailed the core problem: noise. A single measurement can be skewed by a recent workout or illness, while lab-to-lab variation often masks any real biological signal. “These models attempt to compress complex, multi-dimensional systems into one summary number,” he noted, a compression that loses the nuance needed for individual health decisions.
Peter Attia, The Peter Attia Drive:
- While aging clocks are a promising research tool for compressing multidimensional aging into a single metric, they currently lack proven clinical utility for individual health decisions.
- Proven biomarkers like blood pressure, glucose, and lipid levels have decades of evidence linking them directly to clinical outcomes, unlike current aging clock scores.
The disconnect is stark in the data. The DO-HEALTH trial, a large randomized controlled study, tested vitamin D, omega-3s, and exercise in healthy adults over 70 against four epigenetic clocks. The results were inconsistent and underwhelming: omega-3s showed a tiny benefit, roughly three months of "youth" gained over three years. Vitamin D and exercise had almost no measurable effect.
The ultimate litmus test is the insurance industry. Life insurers, whose business depends on precise mortality prediction, ignore epigenetic clocks. They still bet billions on blood pressure, smoking status, and lipid panels. Their payouts rarely deviate from internal models by more than 1%. If clocks offered a superior edge, the industry would have adopted them.
For now, the flashy summary number remains an experimental proxy. We don’t yet know if “turning back the clock” actually prevents heart attacks or dementia.
